If you or someone in your household has narcolepsy, you know how much this condition can affect daily life. People with narcolepsy have fragmented nighttime sleep and extreme sleepiness during the day ...

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Pitolisant ...

INDIANAPOLIS -- Extended-release sodium oxybate (Lumryz) taken once before bedtime was preferred by patients with narcolepsy over twice-nightly dosing and was generally well tolerated, according to ...

Please provide your email address to receive an email when new articles are posted on . Most participants with narcolepsy with cataplexy who took the sodium oxybate therapy Xyrem at the beginning of a ...

Axsome Therapeutics (AXSM) on Wednesday said it received formal pre–New Drug Application (NDA) meeting minutes from the U.S.

Data suggest that pitolisant, a histamine 3-receptor antagonist/inverse agonist under development for narcolepsy treatment, showed limited abuse potential and other benefits, according to findings ...

Narcolepsy, a neurological disorder affecting sleep-wake cycles, impacts one in two thousand people, typically between ages ...

Narcolepsy is a rare condition that will make someone fall asleep abruptly — even in the middle of the day during an activity. It's possible to treat narcolepsy and manage your symptoms with lifestyle ...

NEW YORK, March 25, 2024 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous ...

Oct. 25, 2002 — Low cerebrospinal fluid (CSF) levels of hypocretin are diagnostic for narcolepsy, according to a report in the October issue of Archives of Neurology. Because hypocretin neurons are ...

New Drug Application (NDA) submission on track for January 2026NEW YORK, Dec. 31, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: ...